Breaking News: Benitec Biopharma Inc. Sets Price for $18 Million Public Offering
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the pricing of its underwritten public…